These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22336882)

  • 1. Pharmaco-economic aspects of sipuleucel-T.
    Simoens S
    Hum Vaccin Immunother; 2012 Apr; 8(4):506-8. PubMed ID: 22336882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
    Paller CJ; Antonarakis ES
    Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
    Wesley JD; Whitmore J; Trager J; Sheikh N
    Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
    Gaines KK
    Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
    Holko P; Kawalec P
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years of Provenge.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253
    [No Abstract]   [Full Text] [Related]  

  • 8. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH; Kockler DR
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Nabhan C
    N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
    [No Abstract]   [Full Text] [Related]  

  • 11. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
    Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood cells and their use in active immunotherapy of prostate cancer.
    Zhang SY; Thara E; Quinn DI; Dorff TB
    Hum Vaccin Immunother; 2012 Apr; 8(4):528-33. PubMed ID: 22370509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
    Madan RA; Aragon-Ching JB; Gulley JL; Dahut WL
    Expert Rev Vaccines; 2011 Jun; 10(6):743-53. PubMed ID: 21692697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.